Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491135 | 1.00 | TSHR (0.52) | TSHRALDH1A1LMNAEGFRCA2 | |
| SCHEMBL5649 | 0.85 | CYP1A2 (0.43) | TSHRALDH1A1LMNATDP1CA6 | |
| SCHEMBL3784650 | 0.82 | ALOX15 (0.47) | TSHRALDH1A1LMNAEGFRCA2 | |
| SCHEMBL29469267 | 0.74 | GAA (0.42) | TSHRLMNAHPGDCYP1A2CYP2A6 | |
| SCHEMBL31590137 | 0.74 | TSHR (0.48) | TSHRALDH1A1LMNACA2HPGD | |
| SCHEMBL24476855 | 0.74 | TSHR (0.48) | TSHRALDH1A1LMNACA2HPGD | |
| SCHEMBL29957352 | 0.74 | ALDH1A1 (0.39) | TSHRALDH1A1LMNACA2CA1 | |
| SCHEMBL31482537 | 0.74 | CYP1A2 (0.35) | TSHRALDH1A1LMNACA2TDP1 | |
| SCHEMBL321378 | 0.74 | GAA (0.42) | TSHRLMNAHPGDCYP1A2CYP2A6 | |
| SCHEMBL15750735 | 0.74 | ALDH1A1 (0.39) | TSHRALDH1A1LMNACA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829557-B | Pentaheterocycle compound, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4446327-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2025-09-24 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| EP-4254527-B1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEMICAL LTD (KR) | 2025-07-30 | — | — | EP | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250160207-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-05-15 | — | — | US | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| EP-2888266-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2888266-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | TSHR 2869/4885ALDH1A1 4287/4885LMNA 1315/4885 |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | TSHR 2965/4885ALDH1A1 26/4885LMNA 1486/4885 |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | TSHR 2944/4885ALDH1A1 917/4885LMNA 853/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885ALDH1A1 4162/4885LMNA 2823/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | TSHR 2965/4885ALDH1A1 26/4885LMNA 1486/4885 |
| US-20250160207-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LEF1, CRY1, CYP1A1 | TSHR 4566/4885ALDH1A1 28/4885LMNA 2674/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885LMNA 3885/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885ALDH1A1 4162/4885LMNA 2823/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4359/4885ALDH1A1 4162/4885LMNA 2823/4885 |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | TSHR 4837/4885ALDH1A1 3327/4885LMNA 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.